XML 34 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisitions, Investments, and Licenses - Schedule of Consolidated Assets and Non-Recourse Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Jun. 30, 2014
Dec. 31, 2013
Current assets:        
Cash and cash equivalents $ 221,217 [1] $ 96,907 [1] $ 134,010 $ 185,798
Accounts receivable, net [1] 26,980 19,969    
Inventory, net [1] 20,519 16,604    
Prepaid expenses and other current assets [1] 9,623 9,389    
Total current assets [1] 278,339 142,869    
Property, plant and equipment, net [1] 23,405 16,411    
Intangible assets, net [1] 94,247 62,649    
Goodwill [1] 289,607 224,292    
Other assets [1] 6,013 5,838    
Total assets [1] 1,525,491 1,267,664    
Current liabilities:        
Accounts payable [1] 16,039 8,744    
Accrued expenses [1] 149,843 60,912    
Total current liabilities [1] 180,481 83,111    
Other long-term liabilities [1] 408,821 217,358    
Total liabilities [1] 698,505 431,923    
SciVac | Variable Interest Entity, Primary Beneficiary        
Current assets:        
Cash and cash equivalents 21 393    
Accounts receivable, net 304 316    
Inventory, net 1,433 1,649    
Prepaid expenses and other current assets 774 718    
Total current assets 2,532 3,076    
Property, plant and equipment, net 1,791 1,725    
Intangible assets, net 843 875    
Goodwill 1,602 1,553    
Other assets 368 384    
Total assets 7,136 7,613    
Current liabilities:        
Accounts payable 900 445    
Accrued expenses 4,476 4,446    
Notes payable 5,409 5,189    
Total current liabilities 10,785 10,080    
Other long-term liabilities 1,884 2,042    
Total liabilities $ 12,669 $ 12,122    
[1] As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.